[HTML][HTML] Revisiting nomenclature for the description of prostate cancer androgen-responsiveness
HV Heemers, JL Mohler - American Journal of Clinical and …, 2014 - ncbi.nlm.nih.gov
Ever since the Noble prize-winning findings of Huggins and Hodges, the androgen receptor
(AR) has been the main target for treatment of advanced prostate cancer (CaP). Today …
(AR) has been the main target for treatment of advanced prostate cancer (CaP). Today …
Combination of Nexrutine and docetaxel suppresses NFκB‐mediated activation of c‐FLIP
Y Zhang, L Li, J Wang, W Cheng, J Zhang… - Molecular …, 2017 - Wiley Online Library
Lack of effective options following failure to conventional chemotherapeutic agent such as
Docetaxel (DX) is a major clinical challenge in the management of prostate cancer. These …
Docetaxel (DX) is a major clinical challenge in the management of prostate cancer. These …
[图书][B] Complementary and Alternative Medicines in Prostate Cancer: A Comprehensive Approach
KB Harikumar - 2016 - taylorfrancis.com
Recent global cancer statistical data has clearly indicated that prostate cancer is currently
the second most frequently diagnosed cancer (at 15% of all male cancers) and globally the …
the second most frequently diagnosed cancer (at 15% of all male cancers) and globally the …
[HTML][HTML] Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
M Elbanna, HV Heemers - Discovery medicine, 2014 - discoverymedicine.com
Prostate cancer (CaP) is the most frequently diagnosed cancer and the second leading
cause of cancer deaths in men in the US CaP deaths are due to failure of androgen …
cause of cancer deaths in men in the US CaP deaths are due to failure of androgen …
Prostate Cancer: An Introduction
M Babu, Y Vijayan, KB Harikumar - … and Alternative Medicines in …, 2016 - books.google.com
1.5 Tumor Microenvironment 1.6 Disease Progression and PSA Levels 1.7 Signaling
Pathways Regulate Certain Hallmarks of PC 1.7. 1 Sustained Proliferative Signaling 1.7. 2 …
Pathways Regulate Certain Hallmarks of PC 1.7. 1 Sustained Proliferative Signaling 1.7. 2 …
CYP17A1 polymorphisms and clinical outcome of patients with metastatic castration-resistant prostate cancer treated with abiraterone
UFF De Giorgi - 2014 - amsdottorato.unibo.it
Background. Abiraterone acetate is a potent inhibitor of cytochrome P450 17 α-hydrolase
(CYP17A1) that causes a reduction in the synthesis of testosterone in the adrenal glands …
(CYP17A1) that causes a reduction in the synthesis of testosterone in the adrenal glands …
[PDF][PDF] Immunohistochemical Evaluation of Androgen Receptor and Nerve Structure
C Di Loreto, F La Marra, G Mazzon, E Belgrano… - pone …, 2014 - academia.edu
Finasteride is an inhibitor of 5-o-reductase used against male androgenetic alopecia (AGA).
Reported side effects of finasteride comprise sexual dysfunction including erectile …
Reported side effects of finasteride comprise sexual dysfunction including erectile …